Business Segments Clause Samples

Business Segments. Schedule S-1 accurately sets forth each Business Segment of the Loan Parties and the Subsidiaries of Parent included in each such Business Segment as of the Closing Date.

Business Segments. CSW's business segments at December 31, 1997 included the U.S. Electric operations (CPL, PSO, SWEPCO, WTU) and the United Kingdom Electric operations (SEEBOARD U.S.A.). See NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES for a discussion of the accounting for the SEEBOARD acquisition. Eight additional non-utility companies are included with CSW in Corporate items and Other (CSW Energy, CSW International, C3 Communications, CSW Credit, CSW Leasing, CSW Services, EnerShop and CSW Energy Services). Gas Operations (Transok) were sold on June 6, 1996. See NOTE 15. TRANSOK DISCONTINUED OPERATIONS for additional information. CSW's business segment information is presented in the following tables. 1997 1996 1995 -------- -------- -------- (millions) OPERATING REVENUES Electric Operations United States $3,321 $3,248 $2,883 United Kingdom (1) 1,870 1,848 208 Corporate items and Other 77 59 52 -------- -------- -------- $5,268 $5,155 $3,143 -------- -------- -------- OPERATING INCOME Electric Operations United States $661 $768 $719 United Kingdom (1) 255 236 21 Corporate items and Other (30) 15 (27) -------- -------- -------- Operating income before taxes 886 1,019 713 Income taxes (151) (224) (92) -------- -------- -------- $735 $795 $621 -------- -------- -------- DEPRECIATION AND AMORTIZATION Electric Operations United States $389 $362 $335 United Kingdom (1) 92 88 7 Corporate items and Other 16 14 11 -------- -------- -------- $497 $464 $353 -------- -------- -------- IDENTIFIABLE ASSETS Electric Operations United States $9,172 $9,142 $9,278 United Kingdom (1) 2,931 3,061 2,821 Corporate items and Other 1,348 1,129 1,004 -------- -------- -------- 13,451 13,332 13,103 Gas Operations (Discontinued) -- -- 766 -------- -------- -------- $13,451 $13,332 $13,869 -------- -------- -------- CAPITAL EXPENDITURES AND ACQUISITIONS Electric Operations United States $346 $356 $398 United Kingdom (1), (2) 126 1,543 731 Corporate items and Other (3) 276 109 19 -------- -------- -------- 748 2,008 1,148 Gas Operations (Discontinued) -- 23 66 -------- -------- -------- $748 $2,031 $1,214 -------- -------- -------- (1) Represents equity method of accounting for November 1995 (27.6%) and full consolidation accounting for December 1995 (76.45%). (2) Includes $1,394 million and $731 million in 1996 and 1995, respectively, used to purchase SEEBOARD. (3) Includes CSW Energy and CSW International equity investments.

Business Segments. (i) Suspend the operation of a segment material to the operation of its business as presently conducted, which suspension could materially impair the operations of the Borrower and its Subsidiaries taken as a whole; or (ii) engage at any time in any business or business activity other than the business currently conducted by it and business activities reasonably incidental thereto.

Business Segments. Datacenter Hosting Business Cloud Services HPC Hosting Business

Business Segments. The Borrower will not, and will not permit any Subsidiary to, (i) suspend the operation of a segment material to the operation of its business as presently conducted, which suspension could materially impair the operations of the Borrower and its Subsidiaries taken as a whole; or (ii) engage at any time in any business or business activity other than the business currently conducted by it and business activities reasonably incidental thereto.

Business Segments. The Company operates in one segment and therefore segment information is not presented.

Business Segments. The Company has three reportable segments: Consumer Products, Companion Pet Products and Poultry Vaccines. Products from each of the segments serve different markets, use different channels of distribution, and, for two of the segments, have different forms of government oversight. Consumer Products Business IGI's Consumer Products business is primarily focused on the continued commercial use of the Novasome(R) microencapsulation technologies for skin care applications. These efforts have been directed toward the development of high quality skin care products marketed by the Company or through collaborative arrangements with cosmetic and consumer products companies. Revenues from the Company's Consumer Products business were principally based on formulations using the Novasome(R) encapsulation technology. Sales to ▇▇▇▇▇ ▇▇▇▇▇▇ accounted for $4,237,000 or 13% of 1999 sales, $3,494,000 or 11% for 1998, and $2,408,000 or 7% in 1997. Companion Pet Products The Company sells its Companion Pet Products to the veterinarian market under the EVSCO Pharmaceuticals trade name and to over-the-counter ("OTC") pet products market under the Tomlyn and Luv'Em labels. The EVSCO line of veterinary products is used by veterinarians in caring for dogs and cats, and includes pharmaceuticals such as antibiotics, anti-inflammatories and cardiac drugs, as well as nutritional supplements, vitamins, insecticides and diagnostics. Product forms include gel, tablets, creams, liquids, ointments, powders, emulsions and shampoos. EVSCO also produces professional grooming aids for dogs and cats. EVSCO products are manufactured at the Company's facility in Buena, New Jersey and are sold through distributors to veterinarians. The facility operates in accordance with Good Manufacturing Practices ("GMP") of the federal Food and Drug Administration ("FDA"). The Tomlyn product line includes pet grooming, nutritional and therapeutic products, such as shampoos, grooming aids, vitamin and mineral supplements, insecticides and OTC medications. The products are manufactured at the Company's facility in Buena, New Jersey, and are sold directly to pet superstores and through distributors to independent merchandising chains, shops and kennels. Most of the Company's veterinary products are sold through distributors. Poultry Vaccines The Company produces and markets poultry vaccines manufactured by the chick embryo, tissue culture and bacteriologic methods. The Company produces vaccines for the preventio...

Business Segments. Supply base and port operations Infrastructure development and operations

Business Segments. The Company operated in two business segments during the reporting periods: (i) the Retail Drug segment, and (ii) the Pharmacy Benefit Management ("PBM") segment, which includes pharmacy benefit management, mail-order pharmacy services, marketing prescription plans and other managed health care services. The Company's business segments are organized according to the products and services offered to its customers. The Company's dominant segment is the Retail Drug segment, which consists of the operation of retail drugstores across the United States. The drugstores' primary business is pharmacy services, with prescription drugs RITE AID CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS--(Continued) (Dollars in thousands, except share amounts) (unaudited) accounting for approximately 59.8 percent and 58.5 percent of total segment sales for the twenty-six week periods ended August 26, 2000 and August 28, 1999, respectively. In addition, the Company's drugstores offer a full selection of health and personal care products, seasonal merchandise and a large private label product line. The Company operated a PBM segment, principally through the operations of PCS Health Systems, Inc. (PCS), which was acquired in January 1999. Through its PBM segment, the Company offered pharmacy benefit management, mail-order pharmacy services, marketing prescription plans and other managed health care services to employers, health plans and their members and government-sponsored employee benefit programs. On July 12, 2000, the Company announced that it had entered into an agreement to sell its PBM segment to Advance Paradigm Inc. The sale was consummated on October 2, 2000. As a result of the agreement and sale of PCS, the PBM segment has been reclassified and is accounted for as a discontinued operation in the accompanying financial statements. Accordingly, the Company's continuing operations consist solely of the Retail Drug segment. Discontinued Operations On July 12, 2000, the Company announced that it had entered into an agreement to sell PCS, its PBM segment, to Advance Paradigm, Inc. The sale of PCS was consummated on October 2, 2000. The selling price of PCS consisted of $675,000 in cash; $200,000 in principal amount of Advance Paradigm's unsecured 10 year senior subordinated notes (with warrants attached) and $125,000 in liquidation preference of Advance Paradigm's 11% Series A Preferred Stock. The senior subordinated notes bear interest at ...